Advertisement

Rheumatology International

, Volume 33, Issue 3, pp 681–688 | Cite as

Excess weight and associated risk factors in patients with systemic lupus erythematosus

  • Fabiana de Miranda Moura dos Santos
  • Mariane Curado BorgesEmail author
  • Rosa Weiss Telles
  • Maria Isabel T. D. Correia
  • Cristina Costa Duarte Lanna
Original Article

Abstract

The objective of this study is to determine the socio-demographic, clinical and laboratory characteristics of outpatients with SLE who present with excess weight as well as to assess the immunosuppressive therapy used. One hundred and seventy women with SLE were evaluated consecutively in a transversal study. The relationship between excess weight and the patients’ characteristics was evaluated using univariate and multivariate Poisson regression analysis. Of the 170 patients evaluated, 109 presented with excess weight, two were malnourished and 59 were classified as eutrophic. Age and disease duration of those with excess weight were 42.4 ± 8.7 and 10.4 ± 6.2 years, respectively. Risk factors associated with excess weight were the following: age ≥40 years, <8 years of education, lack of occupation, damage index ≥1, systemic high blood pressure, diabetes mellitus and triglycerides ≥150 mg/dL levels. The use of antimalarial therapy and steroids was associated with a lower frequency of excess weight. Age ≥40 years and the non-usage of methotrexate were the variables independently associated with excess weight in the multivariate analysis. Patients with SLE who have excess weight present distinct clinical-laboratory findings, socio-demographic characteristics and treatment options when compared to normal weight patients. Prospective studies should assess whether these characteristics will interfere with the outcome or prognosis of lupus.

Keywords

Systemic lupus erythematosus Excess weight Nutritional status 

Notes

Acknowledgments

We acknowledge the FAPEMIG (The State of Minas Gerais Research Foundation) for financial support and the CNPQ (Conselho Nacional de Desenvolvimento Científico e Tecnológico) for the research grant to Correia, MITD.

Conflict of interest

None of the authors has declared a conflict of interest.

References

  1. 1.
    World Health Organization. Fact sheet: obesity and overweight. Available at http://www.who.int/mediacentre. Accessed on: 11 Jun. 2008
  2. 2.
    Oeser A, Chung CP, Asanuma Y, Avalos I, Stein M (2005) Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 52(11):3651–3659PubMedCrossRefGoogle Scholar
  3. 3.
    Chaiamnuay S, Bertoli AM, Fernández M, Apte M, Vilá LM, LUMINA Study Group et al (2007) The impact of increased body mass index on systemic lupus erythematosus. J Clin Rheumatol 13(3):128–133PubMedCrossRefGoogle Scholar
  4. 4.
    Petri M (2000) Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 9:170–175PubMedCrossRefGoogle Scholar
  5. 5.
    Lee S–S, Singh S, Magder LS, Petri M (2008) Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus. Lupus 17:114–123PubMedCrossRefGoogle Scholar
  6. 6.
    Bultink IEM (2010) Prospective cohort studies on risk factors for cardiovascular events in systemic lupus erythematosus: a major challenge. Arthritis Res Ther 12(107–108):107PubMedCrossRefGoogle Scholar
  7. 7.
    Tan EM, Cohen AS, Fries JF (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982(25):1271–1277CrossRefGoogle Scholar
  8. 8.
    Hochberg MC (1997) Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRefGoogle Scholar
  9. 9.
    Onis M, Habicth JP (1996) Anthropometric reference data for international use: recommendations from a world health organization expert committee health organization. Am J Clin Nutr 64:650–658PubMedGoogle Scholar
  10. 10.
    Luiz RA, Magnanimi MMF (2004) Size of samples in epidemiological investigations In: Medronho R. Epidemiologia. 2a ed. São Paulo: Atheneu. Cap.10, p 415–427Google Scholar
  11. 11.
    V Brazilian Guidelines on Hypertension. Arq Bras Cardiol 2007;89(3):e24–e79Google Scholar
  12. 12.
    American Diabetes Association (2004) Diagnosis and classification of diabetes mellitus. Diabetes Care 27:S5–S10CrossRefGoogle Scholar
  13. 13.
    Lawrence NM (2009) Primary ovarian insufficiency. N Engl J Med 360(6):606–614CrossRefGoogle Scholar
  14. 14.
    Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291PubMedGoogle Scholar
  15. 15.
    Gladman DD, Ginzler EM, Goldsmith C, Fortin P, Liang M, Urowitz M et al (1996) The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369PubMedCrossRefGoogle Scholar
  16. 16.
    Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE et al (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35:1381–1395PubMedCrossRefGoogle Scholar
  17. 17.
    Matsudo SM, Araújo T, Matsudo VR, Andrade D, Andrade E, Oliveira LC et al (2001) International physical activity questionnaire (IPAQ): reproducibility and validity study in Brazil. Rev Bras Física Saúde 6:5–18Google Scholar
  18. 18.
    Celafisc (2007) Physical activity classification—IPAQ. Brazil. Available at: http://www.celafisc.institucional.ws/65/questionarios.html. Accessed on 9 Sep. 2009
  19. 19.
    Bernatsky S, Biovin JF, Josefh L, Pierre YST, Moore A, Rajan R et al (2002) Prevalence of factors influencing cancer risk in women with lupus: social habits, reproductive issue, and obesity. J Rheumatol 29:2551–2554PubMedGoogle Scholar
  20. 20.
    Ministry of Health. Surveillance and risk factors for chronic disease through telephone interviews. Brazil; 2008. Available at: http://www.saude.gov.br. Accessed on 2 Nov. 2009
  21. 21.
    Telles RW, Lanna CCD, Ferreira GA, Carvalho MA, Ribeiro AL (2007) Frequency of atherosclerotic cardiovascular disease and its risk factors in patients with systemic lupus erythematosus. Rev Bras Reumatol 47(3):165–172CrossRefGoogle Scholar
  22. 22.
    Haas E, Bhattacharya I, Brailoiu E, Damjanovic M, Brailoiu CG, Gao X et al (2009) Regulatory role of G protein coupled estrogen receptor for vascular function and obesity. Circ Res 104:288–291PubMedCrossRefGoogle Scholar
  23. 23.
    Williamson DF, Kahn HS, Remington PL, Anda RF (1990) The 10-year incidence of overweight and major weight gain in US adults. Arch Intern Med 150:665–672PubMedCrossRefGoogle Scholar
  24. 24.
    Jeffey RW, French SA (1996) Socioeconomic status and weight control practices among 20- to 45-year-old women. Am J Public Health 86(7):1005–1010CrossRefGoogle Scholar
  25. 25.
    Alarcón GS, McGwin GJr, Bastian HM, Roseman J, Lisse J, Fessler BJ et al (2001) for the Lumina study group Systemic Lupus Erythematosus in Three Ethnic Groups. VIII. Predictors of Early Mortality in the LUMINA Cohort. Arthritis Rheum 45(2):191–202Google Scholar
  26. 26.
    Sabio JM, Zamora-Pasadas M, Jiménez-Jáimez J, Albadalejo F, Vargas-Hitos J et al (2008) Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus 17:849–859PubMedCrossRefGoogle Scholar
  27. 27.
    Bellomio V, Spindler A, Lucero E, Berman A, Sueldo R et al (2009) Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus 18:1019–1025PubMedCrossRefGoogle Scholar
  28. 28.
    Petri M, Perez-Gutthann S, Spence D, Hochberg MC (1992) Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93:513–519PubMedCrossRefGoogle Scholar
  29. 29.
    Cardoso CRL, Signorelli F, Papi JA, Salles GF (2008) Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients. Reumatol Int 28:323–327CrossRefGoogle Scholar
  30. 30.
    Petri M (1996) Hydroxychloroquine used in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 5:S16–S22PubMedCrossRefGoogle Scholar
  31. 31.
    Borba EF, Bonfa E (2001) Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 28:780–785PubMedGoogle Scholar
  32. 32.
    Fessler BJ, Alarcón G, McGwin Jr G, LUMINA Study Group et al (2005) Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 52:1473–1480Google Scholar
  33. 33.
    Irastorza RG, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Berrriota MA et al (2006) Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15:577–583CrossRefGoogle Scholar
  34. 34.
    Fortin PR, Abrahamowic M, Ferland D, Lacaille D, Smith CD, Zummer M (2008) Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 59(13):1796–1804PubMedCrossRefGoogle Scholar
  35. 35.
    Wong JM, Esdaile JM (2005) Methotrexate in systemic lupus erythematosus. Lupus 14:101–105PubMedCrossRefGoogle Scholar
  36. 36.
    Sánchez Y, Carvallo A (2004) Methotrexate use in patients with systemic lupus erythematosus. Rev Méd Chile 132:195–201PubMedGoogle Scholar
  37. 37.
    Ogden CL, Carroll M, Curtin LR, McDowell MA, Flegal KM (2006) Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 295:1549–1555PubMedCrossRefGoogle Scholar
  38. 38.
    Kunitoshi I, Yoshiharu I, Kozen K, Taku I, Chiho I, Shuichi T (2004) Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 65:1870–1876CrossRefGoogle Scholar
  39. 39.
    Tench CM, McCarthy J, McCurdie I, White PD, Cruz DPD (2003) Fatigue is systemic lupus erythematosus: a randomized controlled trial of exercise. Rheumatology 42:1050–1054PubMedCrossRefGoogle Scholar
  40. 40.
    Carvalho MRP, Sato E, Tebexreni AS, Heidecher RTC, Schenkman S, Neto TLB (2005) Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity and quality of life in patients with systemic lupus erythematosus. Arthritis Rheum 53:838–844PubMedCrossRefGoogle Scholar
  41. 41.
    Ayán C, Martín V (2007) Systemic lupus erythematosus and exercise. Lupus 16:5–8PubMedCrossRefGoogle Scholar
  42. 42.
    Tench C, Bentley D, Vleck V, Mccurdie I, White P, D’Cruz D (2002) Aerobic fitness, fatigue, and physical disability in systemic lupus erythematosus. J Rheumatol 29:474–481PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Fabiana de Miranda Moura dos Santos
    • 1
  • Mariane Curado Borges
    • 2
    Email author
  • Rosa Weiss Telles
    • 1
  • Maria Isabel T. D. Correia
    • 3
  • Cristina Costa Duarte Lanna
    • 1
    • 4
  1. 1.Rheumatology Service, Hospital das Clínicas, Department of Locomotor System, School of MedicineUniversidade Federal de Minas GeraisBelo HorizonteBrazil
  2. 2.School of MedicineUniversidade Federal de Minas GeraisBelo HorizonteBrazil
  3. 3.Department of Surgery, School of MedicineUniversidade Federal de Minas GeraisBelo HorizonteBrazil
  4. 4.Department of Locomotor System, School of MedicineUniversidade Federal de Minas GeraisBelo HorizonteBrazil

Personalised recommendations